Author: Condie Carmack

More of Its Money and a Little Help from Washington: How Pfizer Won Metsera

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington. Novo Nordisk has given up on trying to outbid Pfizer to acquire the obesity and metabolic drug developer after one-upping the pharma giant last week. Metsera […]

Will Lower GLP-1 Prices Undermine Novo Nordisk’s Near-Term Outlook?

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). Following President Trump’s comments last month on forthcoming government action to reduce the prices of Ozempic and Wegovy, Novo Nordisk disclosed last week that it has reached […]

Weight-loss pills replacing GLP-1 shots will be ready by March, Dr. Oz tells FOX Business

Oral weight loss pills will be replacing GLP-1 shots by March of 2026, Medicare and Medicaid Services Administrator Dr. Mehmet Oz predicted on Monday. Oz made the statement during a Monday morning appearance on Fox Business’ “Mornings With Maria,” where he discussed the Trump administration’s wider push to improve Americans’ health. “These pharma companies are […]

The Trump administration’s drug deals, explained

In the closing months of 2025, President Donald Trump’s effort to reshape how Americans pay for prescription drugs has taken clearer form. What started as a campaign threat to slap tariffs on pharmaceutical imports has evolved into a series of deals with some of the world’s largest drugmakers — and a promise that patients in […]

STAT+: Medicaid’s ‘GENEROUS’ pricing may not save states money

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning, morning. Today, we have a trio of interesting studies on cholesterol reduction from the American Heart Association’s meeting in New Orleans. Also, Pfizer wins the Metsera deal with $10 billion, and we look […]

Does Trump’s MFN Policy Put Pharma ETFs in the Crosshairs?

Pharma giants Eli Lily (LLY) and Novo Nordisk (NVO) have signed deals with U.S. President Donald Trump to slash the prices of some of their obesity drugs, including upcoming pills, as per a White House announcement made late last week. This comes as part of the Trump administration’s Most-Favored-Nation (“MFN”) drug pricing policy that aims […]